Biopharmx (NYSEAMERICAN:BPMX) received a $3.00 target price from investment analysts at Maxim Group in a research report issued to clients and investors on Wednesday, TipRanks reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price points to a potential upside of 251.91% from the company’s previous close.
Shares of BPMX opened at $0.85 on Wednesday. Biopharmx has a 1-year low of $0.81 and a 1-year high of $6.75.
Biopharmx (NYSEAMERICAN:BPMX) last posted its quarterly earnings results on Tuesday, June 11th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.12).
An institutional investor recently raised its position in Biopharmx stock. Deutsche Bank AG boosted its stake in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) by 1,256.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 549,973 shares of the biotechnology company’s stock after purchasing an additional 509,430 shares during the period. Deutsche Bank AG owned approximately 0.25% of Biopharmx worth $59,000 at the end of the most recent reporting period.
Biopharmx Company Profile
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Recommended Story: Earnings Per Share (EPS)
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.